(Press-News.org) Fat cells — liposuctioned from a patient's belly — can safely boost heart function after a heart attack, according to a first-of-its-kind study presented at the American Heart Association's Scientific Sessions 2010.
"The study suggests that these cells can be safely obtained and infused inside the hearts of patients following an acute heart attack," said Eric (HJ) Duckers, M.D., Ph.D., lead author of the small study and head of Molecular Cardiology Laboratory at the Thoraxcenter, Erasmus University Medical Center in Rotterdam, Netherlands.
The treatment reduced the amount of damaged heart tissue, increased blood flow in the heart and improved the heart's pumping ability. These changes were not statistically significant, but the fat-derived stem cells worked as expected, Duckers said.
Duckers and colleagues recruited 11 men and three women for the prospective, double-blind, placebo-controlled APOLLO study (A Randomized Clinical Trial of AdiPOse-Derived Stem ceLLs in the Treatment of Patients With ST-Elevation myOcardial Infarction). They randomized the 14 patients — 10 received stem cells and four got a placebo infusion. All patients had suffered a severe heart attack and had a catheter procedure to evaluate their heart damage within two to 12 hours of symptom onset.
With the patients' consent, researchers liposuctioned 200-250 cubic centimeters of fat from the abdomen of each, using a system called Celution 800 device (Cytori Tx). From the fat cells, they isolated 20 million regenerative stem cells, which took nine to 10 minutes to infuse.
With the Celution device, physicians can isolate and sometimes infuse stems cells into the heart while the original catheter is still in place. APOLLO participants received cells within 24 hours after their catheterization.
At six months follow-up, researchers found encouraging results in the treatment group:
Those receiving stem cells showed a 3.5-fold improvement in heart perfusion. The treatment arm also had a 5.7 percent increase in the amount of blood ejected by the left ventricle versus those receiving placebo.
The average size of heart muscle damage dropped from 31.6 percent to 15.4 percent in the treatment group. For the placebo arm, the average area of damage remained the same as when the patients enrolled in the study — i.e. 24.7 percent.
The infused stem cells did not interfere with blood flow in the heart.
Stem cell therapy was not associated with ventricular arrhythmias, which are potentially fatal erratic heartbeats.
Two patients experienced adverse events from the liposuction procedure. Both formed a hematoma, an area of swelling filled with blood.
Although the APOLLO patients were white Europeans from the Netherlands (13) and Spain (one), "findings in the European Union population should be directly applicable to the United States population," Duckers said. "But, it's unclear whether the results would apply to non-Caucasians."
APOLLO's major limitation is its small size, and therefore its low statistical power to detect differences. This may be why researchers didn't find a significant difference between the treatment and placebo groups.
Duckers and his colleagues have initiated a phase II-III clinical trial called ADVANCE that will enroll up to 375 patients at 35 medical centers in the European Union. It will focus on acute heart attack patients with a left ventricle ejection fraction less than 45 percent. Forty percent of patients will receive 20 million stem cells; another 40 percent will get 30 million stem cells; and 20 percent will make up the placebo group.
"The primary efficacy endpoint of ADVANCE will be absolute improvement in infarct size at six months follow-up," Duckers said. "Several studies have shown that this is an excellent and more consistent predictor of survival and major adverse events (than other endpoints) in patients after an acute heart attack."
###Co-authors are: Jaco Houtgraaf, M.D., Ph.D.; Robert Jan van Geuns, M.D., Ph.D.; Bas. D. van Dalen, M.D., Ph.D.; Evelien Regar, M.D., Ph.D.; Wim van der Giessen, M.D., Ph.D.; Peter de Jaegere, M.D., Ph.D.; C. Schultz, M.D., Ph.D.; Michael Martin, M.D., Ph.D.; Alexander Milstein, M.D., Ph.D.; F. J. Fernandez-Aviles, M.D., Ph.D.; and Patrick. W. Serruys, M.D., Ph.D. Author disclosures are on the abstract. Cytori Therapeutics, Inc. funded the study.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
NR10-1154 (SS10/Duckers)
Additional resources:
Multimedia resources (animation, audio, video, and images) are available in our newsroom at Scientific Sessions 2010 - Multimedia. This will include audio interview clips with AHA experts offering perspective on news releases. Video clips with researchers will be added to this link after each embargo lifts.
Stay up to date on the latest news from American Heart Association scientific meetings, including Scientific Sessions 2010, by following us at www.twitter.com/heartnews. We will be tweeting from the conference using hashtag #AHA10News.
END
Abstract 21829 – Automated remote patient monitoring fails to improve outcomes for heart failure patients
A remote monitoring system didn't help heart failure patients live longer or avoid return trips to the hospital, according to a new study.
The system required heart failure patients to dial into an automated, interactive voice response system daily to enter their weight and answer questions about heart failure symptoms. Clinicians managing patients' heart failure reviewed the information and called patients back to discuss worrisome reports. The remote monitoring ...
Years of research are the basis for the latest drugs and treatments for cardiovascular disease. This discussion will highlight early and pre-clinical research that may well be the foundation of treatments to come. Join us for an informal Q&A with researchers who are passionate about the details of battling cardiovascular disease. We'll discuss a range of topics, from a possible drug target to regulate HDL cholesterol, to injectable goo that boosts heart function, and heart cell "balls" that take cellular therapy to another dimension.
Abstract 21739 —Researchers discover ...
9 a.m. Abstract 18350 – Explanted re-sterilized ICDs are safe, practical for patient use.
Implantable cardioverter defibrillators (ICDs) removed for upgrades or infection may be reused safely in other patients.
Researchers sent explanted ICDs with 70 percent or more battery life to India, where the devices were carefully cleaned and re-sterilized. They were re-implanted in indigent patients who were at risk of life-threatening arrhythmias but couldn't afford the devices.
Thirty-one patients received explanted, re-sterilized ICDs for standard ICD indications. During ...
Systematic education in rural and suburban communities can significantly shorten onset to hospital arrival times for patients with chest pain, according to study findings to be presented Nov. 16 at the 2010 annual American Heart Association (AHA) Scientific Sessions in Chicago.
Time to treatment is the key determinant of outcome in patients with acute heart attacks, or ST-elevation myocardial infarction (STEMI). Although the total time to reperfusion (chest pain onset to balloon) is critical, the major focus has been on decreasing door-to-balloon (D2B) times since the ...
Contact: Helene R. White, Ph.D.
hewhite@rci.rutgers.edu
732-445-3579
Rutgers University
Andrew Littlefield, Ph.D. Candidate
akl9af@mail.mizzou.edu
573-884-1485
University of Missouri
Alcoholism: Clinical & Experimental Research
Impulsive behavior in males increases after periods of heavy drinking
New findings indicate that adoelscent males that engage in heavy drinking behavior are more likely to engage in risk-taking behavior
Impulsive behavior is well known to be caused by acute ingestion of alcohol
New findings show that periods of heavy drinking by ...
Energy drinks are commonly consumed by teens and college students
A new study shows that energy drink consumption is strongly associated with increased risks for heavy drinking and alcohol dependence
These results call for more scrutiny regarding the possible negative health effects of energy drinks and public education about the risks of consuming energy drinks with alcohol
A hallmark of college life is staying up late to study for an exam the following morning, and many students stay awake by consuming an energy drink. Also increasing in popularity is the practice ...
Cognitive and behavioral deficits have been found in children with Fetal Alcohol Syndrome (FAS), which is extremely difficult to diagnose
New findings indicate that those children, when trained using classical eyeblink conditioning, suffer from deficits in both learning and memory
Using eyeblink conditioning could provide a good model for assessing and diagnosing FAS in children
Fetal alcohol spectrum disorder (FASD) is an irreversible disorder in children that affects the learning centers of the brain and results in cognitive and behavioral impairment in the child ...
Adolescence is a time of significant maturation, physically and emotionally
New findings indicate that adolescents who have a family history of alcohol abuse demonstrated significantly decreased neural activity in the frontal lobe
This could present a unique neurobiological vulnerability for adolescents at risk of developing alcohol abuse
The period known as adolescence is a significant time of change for the individual experiencing it. Some of the most significant changes that occur are located within the prefrontal cortex in the brain, which is involved in decision ...
Using antibiotics to treat newly diagnosed acute ear infections among children is modestly more effective than no treatment, but comes with a risk of side effects, according to a new study designed to help advise efforts to rewrite treatment guidelines for the common illness.
Researchers found no evidence that name-brand antibiotics work any better in general than generic antibiotics and that careful examination of the eardrum by a clinician for signs of infection is critical for accurate diagnosis of acute ear infections. The study is published in the Nov. 17 edition ...
Among the findings of an analysis of previous studies regarding ear infections in children are that results from otoscopic exams (an instrument for examining the interior of the ear) are critical to accurate diagnosis and antibiotics are modestly more effective than no treatment, with most antibiotics demonstrating similar rates of clinical success among children at normal risk, according to an article in the November 17 issue of JAMA.
Acute otitis media (AOM; middle ear infection) is the most common childhood infection for which antibiotics are prescribed in the United ...
